시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 광견병 백신 시장 규모, 점유율, 동향 분석 리포트 : 예방 유형별, 최종사용자별, 용도별, 제품 유형별, 지역별 전망과 예측(2023-2030년)
Global Rabies Vaccine Market Size, Share & Trends Analysis Report By Prophylaxis Type, By End User, By Application, By Product Type, By Regional Outlook and Forecast, 2023 - 2030
상품코드 : 1457271
리서치사 : KBV Research
발행일 : 2024년 03월
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 3,600 ￦ 5,108,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,320 ￦ 6,130,000
PDF (Multi User License) help
PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,048 ￦ 8,582,000
PDF (Corporate User License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계의 광견병 백신 시장 규모는 2030년까지 16억 달러에 달할 것으로 예상되고 있으며, 예측 기간 중 4.5%의 CAGR로 시장 성장이 전망됩니다.

또한 COVID-19 팬데믹으로 인해 백신 접종 프로그램을 포함한 일상적인 의료 서비스가 혼란에 빠졌습니다. 봉쇄, 이동 제한 및 의료 시스템의 압박은 특히 자원이 제한된 지역에서 광견병 예방 접종 캠페인의 실행에 영향을 미칠 수 있습니다. 여행 제한과 세계 교통의 혼란은 세계 보건 노력과 협력에 종사하는 전문가들의 이동에 영향을 미칠 수 있습니다. 이는 광견병을 통제하고 근절하기 위한 전 세계 노력에 영향을 미칠 수 있습니다. 이처럼 COVID-19 팬데믹은 시장에 적당한 영향을 미쳤습니다.

그러나 백신 접종 프로그램의 높은 비용으로 인해, 특히 자원이 부족한 지역에서는 백신에 대한 접근성이 제한될 수 있습니다. 공중 보건을 담당하는 정부는 광견병 예방 접종 프로그램을 시행할 때 재정적 부담을 겪을 수 있습니다. 이러한 프로그램에 자원을 할당하는 것은 다른 중요한 헬스케어 요구 사항과 경쟁 할 수 있으며 예산 제약으로 이어질 수 있습니다. 따라서 높은 비용은 시장 성장을 둔화시킬 수 있습니다.

목차

제1장 시장 범위와 조사 방법

제2장 시장 요약

제3장 시장 개요

제4장 세계 시장 : 예방 유형별

제5장 세계 시장 : 최종사용자별

제6장 세계 시장 : 용도별

제7장 세계 시장 : 제품 유형별

제8장 세계 시장 : 지역별

제9장 기업 개요

제10장 광견병 백신 시장의 성공 필수 조건

KSA
영문 목차

영문목차

The Global Rabies Vaccine Market size is expected to reach $1.6 billion by 2030, rising at a market growth of 4.5% CAGR during the forecast period.

Pet owners increasingly adopt preventive healthcare practices for their animals, mirroring trends in human healthcare. Regular veterinary visits, including vaccinations, are proactive measures to protect pets from diseases such as rabies, fostering a continuous demand for vaccines. Consequently, the Veterinary clinics segment would acquire nearly, 20% market share by 2030. Advancements in veterinary medicine, including the availability of improved and safer vaccines, contribute to a positive perception of vaccinations among pet owners.

Ongoing R&D activities focus on improving the formulation of these vaccines. Researchers work to enhance vaccine stability, reduce adverse reactions, and optimize the immune response. R&D efforts aim to develop next-generation vaccines with enhanced characteristics. This may include vaccines with longer-lasting immunity, novel delivery methods, and the ability to protect against a broader spectrum of rabies virus variants. Therefore, the market is expanding significantly due to the rising research and development (R&D) initiatives. Additionally, Rabies poses a severe threat to human health as it can be transmitted through the saliva of infected animals, primarily through bites or scratches. Zoonotic diseases often transcend national borders, necessitating global collaboration. Collaborative efforts and funding support facilitate the implementation of vaccination programs to control and eliminate rabies, particularly in regions where the disease poses a significant zoonotic threat. Hence, increasing awareness of zoonotic diseases like rabies has been a pivotal factor in driving the growth of the market.

Moreover, The COVID-19 pandemic disrupted routine healthcare services, including vaccination programs. Lockdowns, restrictions on movement, and healthcare system strain may affect the implementation of rabies vaccination campaigns, particularly in regions with limited resources. Travel restrictions and disruptions in global transportation may affected the movement of professionals involved in global health initiatives and collaborations. This impact global efforts to control and eliminate rabies. Thus, the COVID-19 pandemic had a moderate effect on the market.

However, High vaccination program costs can restrict access to these vaccines, particularly in resource-constrained areas. Governments responsible for public health initiatives may experience financial strain when implementing rabies vaccination programs. The allocation of resources to these programs may compete with other essential healthcare needs, potentially leading to budget constraints. Thus, high cost can slow down the growth of the market.

By Prophylaxis Type Analysis

Based on prophylaxis type, the market is classified into pre-exposure prophylaxis and post-exposure prophylaxis. The pre-exposure prophylaxis segment acquired a 40% revenue share in the market in 2022. Pre-exposure prophylaxis offers long-term protection, reducing the need for immediate post-exposure treatment for potential rabies exposure. This long-term protection can be cost-effective in the long run, considering the expenses associated with post-exposure prophylaxis.

By End User Analysis

Based on end user, the market is segmented into hospitals, veterinary clinics, and others. The veterinary clinics segment recorded a 20% revenue share in the market in 2022. A greater demand for veterinary services, such as rabies vaccination, has resulted from the global rise in the prevalence of pet ownership. Routine vaccination programs are integral to the preventive healthcare veterinary clinics provide to pets, including dogs and cats.

By Application Analysis

On the basis of application, the market is bifurcated into human and animal. The animal segment garnered a 30% revenue share in the market in 2022. Animals, particularly mammals, serve as the primary reservoirs of the rabies virus. Controlling rabies in animal populations is essential to reduce the risk of transmission to humans through bites or scratches.

By Product Type Analysis

By product type, the market is categorized into chick embryo cells rabies vaccine, Vero cell rabies vaccine, human diploid cell vaccine, and others. The Vero cell rabies vaccine segment covered a 20% revenue share in the market in 2022. The Vero cell vaccine eliminates the use of nervous tissue in its production, addressing safety concerns associated with traditional nerve tissue-derived vaccines. Removing nervous tissue reduces the risk of adverse reactions, making the Vero cell vaccine a safer option for rabies prevention.

By Regional Analysis

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating 40% revenue share. North America's health authorities and veterinary services implement strategic vaccination programs targeting domestic and wildlife populations. Veterinary clinics and practices across North America actively participate in rabies prevention by providing pet vaccination services.

List of Key Companies Profiled

Global Rabies Vaccine Market Report Segmentation

By Prophylaxis Type

By End User

By Application

By Product Type

By Geography

Table of Contents

Chapter 1.Market Scope & Methodology

Chapter 2.Market at a Glance

Chapter 3.Market Overview

Chapter 4.Global Rabies Vaccine Market by Prophylaxis Type

Chapter 5.Global Rabies Vaccine Market by End User

Chapter 6.Global Rabies Vaccine Market by Application

Chapter 7.Global Rabies Vaccine Market by Product Type

Chapter 8.Global Rabies Vaccine Market by Region

Chapter 9.Company Profiles

Chapter 10.Winning imperative of Rabies Vaccine Market

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기